Nitroglycerin Karo Pharma (Glyceryl Trinitrate)

Glyceryl trinitrate donates nitric oxide, which activates guanylate cyclase in vascular smooth muscle. The resulting rise in cyclic GMP causes relaxation of the muscle, leading to dilation of veins and arteries, decreased myocardial oxygen demand, and improved coronary blood flow.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage adjustments are made under medical supervision to achieve the desired therapeutic effect while minimizing adverse reactions.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Enquiries are submitted via the product page at gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitroglycerin provides rapid onset of action through direct vasodilation, which is useful in acute settings. Other anti‑anginal classes, such as beta‑blockers or calcium‑channel blockers, act more slowly and primarily reduce heart rate or contractility. Choice of therapy depends on clinical urgency, patient comorbidities and physician preference.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperature fluctuations to maintain stability and potency.

The medication is given intravenously under controlled clinical conditions. An infusion pump or syringe driver is typically used to deliver a precise rate, with continuous monitoring of blood pressure and heart rate throughout the administration.

The most serious risks include severe hypotension, which can lead to syncope or organ hypoperfusion, and rare occurrences of methemoglobinemia or anaphylactic reactions. Prompt recognition and immediate medical intervention are essential if these events occur.

Patients with known hypersensitivity to glyceryl trinitrate or any nitrate, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe anemia or uncompensated hypovolemia should avoid this medication unless specifically directed by a physician.